This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Allogeneic bone marrow transplantation

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Allogeneic bone marrow transplantation involves the transfer of marrow from a donor to another person. The donor and recipient may be:

  • monozygotic twins - known as syngeneic transplantation
  • HLA matched siblings
  • unrelated, but closely HLA matched
  • related, but less than perfectly HLA matched

The oldest age for allogeneic transplantation is usually considered to be 40 to 55 years. Increasing age is associated with poorer results due to a higher frequency of graft versus host disease. T cells may be removed from the graft to ameliorate the manifestations of GVHD.

Donation involves the aspiration of about 1L of bone marrow. The recipient is given high dose ablative chemotherapy and, in all but those with aplastic anaemia, total body irradiation. The goals are to:

  • provide sufficient immunosuppression to avoid destruction of the allograft by residual, immunologically active, host cells
  • destroy residual cancer cells
  • provide space for the new marrow to grow

The donor marrow cells are infused intravenously and localise in the marrow. The peripheral blood count rises within 2-4 weeks.

The results of allogeneic transplant undertaken in first complete remission are much better than those in relapse.


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.